The role of high-dose therapy in peripheral T-cell lymphomas

Clinical Lymphoma & Myeloma
Peter ReimerMartin Wilhelm

Abstract

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of non-Hodgkin's lymphomas. With few exceptions (eg, anaplastic large-cell lymphoma expressing the anaplastic lymphoma kinase), PTCLs have generally been reported to have a worse prognosis compared with B-cell lymphomas. Despite the poor outcome after conventional therapy, the impact of high-dose therapy with autologous or allogeneic stem cell transplantation (SCT) in these rare diseases is poorly defined mainly because of the lack of prospective PTCL-restricted studies. Most data exist for high-dose therapy with autologous SCT in relapsing or refractory disease. Because most studies showed similar results for PTCL compared with aggressive B-cell lymphomas in which high-dose therapy with autologous SCT is accepted as standard therapy, this approach seems appropriate in relapsing or refractory PTCL. Results for high-dose therapy with autologous SCT as first-line therapy mainly rely on studies on aggressive lymphomas that also included lymphomas of the T-cell phenotype. Our own recently published PTCL-restricted prospective study confirmed the feasibility with only moderate toxicity and a good response rate. Overall, patients with a good remission status after in...Continue Reading

References

Aug 15, 1984·Cancer·S H SwerdlowA G Stansfeld
Jul 15, 1983·Cancer·G A PangalisH Rappaport
Jan 1, 1997·Bone Marrow Transplantation·R LiangE Chiu
Aug 21, 2001·Drugs·M J Kersten, R H Van Oers
Nov 28, 2001·Hematology·J P GreerT P Loughran
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte
Sep 18, 2003·Bone Marrow Transplantation·P ReimerM Wilhelm
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RodríguezE Conde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Current Hematologic Malignancy Reports
Francesco d'AmoreThomas Relander
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Chitra Hosing, Richard Champlin
© 2022 Meta ULC. All rights reserved